Mercury Biopharmaceutical (ROCO:6932) Retained Earnings: NT$-67.23 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6932 Mercury Biopharmaceutical Corp ROCO:6932
23 GF Score
Price NT$6.02
GF Value NT$36.00
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Mercury Biopharmaceutical Retained Earnings?

Mercury Biopharmaceutical ROCO:6932 -2.43% 23 Retained Earnings is NT$-67.23 Mil as of Dec. 2025. GuruFocus rates ROCO:6932 with a GF Score™ of 23/100 and a GF Value™ of NT$36.00 (Possible Value Trap). The stock has 1 warning sign investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Mercury Biopharmaceutical's retained earnings for the quarter that ended in Dec. 2025 was NT$-67.23 Mil.

Mercury Biopharmaceutical's quarterly retained earnings increased from Dec. 2024 (NT$-50.57 Mil) to Jun. 2025 (NT$-38.33 Mil) but then declined from Jun. 2025 (NT$-38.33 Mil) to Dec. 2025 (NT$-67.23 Mil).

Mercury Biopharmaceutical's annual retained earnings declined from Dec. 2023 (NT$-43.82 Mil) to Dec. 2024 (NT$-50.57 Mil) and declined from Dec. 2024 (NT$-50.57 Mil) to Dec. 2025 (NT$-67.23 Mil).


Mercury Biopharmaceutical  (ROCO:6932) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Mercury Biopharmaceutical Retained Earnings Historical Data

* Premium members only.

The historical data trend for Mercury Biopharmaceutical's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mercury Biopharmaceutical Retained Earnings Chart

Mercury Biopharmaceutical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial -5.31 -31.25 -43.82 -50.57 -67.23

Mercury Biopharmaceutical Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -43.82 -18.30 -50.57 -38.33 -67.23
ROCO:6932
23GF Score
Mercury Biopharmaceutical Corp ROCO:6932
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mercury Biopharmaceutical Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of NT$-67.23 Mil mean?
Mercury Biopharmaceutical (ROCO:6932) has a Retained Earnings of NT$-67.23 Mil as of Dec. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on Mercury Biopharmaceutical and its competitors.
Is Mercury Biopharmaceutical's Retained Earnings too high?
Mercury Biopharmaceutical's current Retained Earnings is NT$-67.23 Mil. Overall, Mercury Biopharmaceutical has a GF Score™ of 23/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mercury Biopharmaceutical's Retained Earnings compare to ZTS?
Mercury Biopharmaceutical's Retained Earnings of NT$-67.23 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Mercury Biopharmaceutical and its competitors. Mercury Biopharmaceutical's current Retained Earnings is NT$-67.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mercury Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Mercury Biopharmaceutical (ROCO:6932) is currently considered Possible Value Trap. The stock's GF Value™ is NT$36.00, compared to a current price of NT$6.02 — trading 83.3% below its estimated fair value. The current Retained Earnings is NT$-67.23 Mil. Mercury Biopharmaceutical's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Mercury Biopharmaceutical (ROCO:6932), the current Retained Earnings is NT$-67.23 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mercury Biopharmaceutical (ROCO:6932) Overvalued in 2026?

Based on GuruFocus' analysis, Mercury Biopharmaceutical stock appears to be undervalued. The current stock price of NT$6.02 is trading 83.3% below its estimated GF Value™ of NT$36.00. GuruFocus considers Mercury Biopharmaceutical to be Possible Value Trap.

Key valuation signals for ROCO:6932:

  • Retained Earnings: NT$-67.23 Mil
  • GF Value™: NT$36.00 vs. price of NT$6.02 (83.3% below fair value)
  • GF Score™: 23/100 with 1 warning sign

No single metric tells the full story. See the ROCO:6932 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mercury Biopharmaceutical Business Description

Address No. 653-1, Bannan Road, 15th Floor, Zhonghe District, New Taipei City, TWN
Mercury Biopharmaceutical Corp focuses on the development of drugs for unmet medical needs. It offers a development platform focusing on rapid release and free adjustable doses. Its 3D powder bonding method (binder jetting) combines powder and special molding adhesive and stacks them in layers.
23GF Score

Get the complete analysis for ROCO:6932

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$6.02
Price
NT$36.00
GF Value